Capital Rx’s Post

Eyedropper bottles are difficult to use. In one study, nearly 20% reported difficulties even getting a drop into their eye. How can ophthalmic drug delivery overcome this and improve patient adherence? TTP’s product development consultants Nathan Wilkinson, Catherine Wyman and Matthew Parker have sized up the possibilities including new delivery modalities, sustained-release therapeutics, and digital healthcare applications. To learn more, read the full insight: https://lnkd.in/eFqxN3QR #ophthalmicdrugdelivery #eyedropper #patientadherence

👀 Looking for a better way to manage data capture, patient-reported outcomes and consent for your next trial? Follow Swing Therapeutics, Inc.’s lead and work smarter, not harder, with #Medrio #CDMS/ #EDC, #eCOA/ #ePRO, and #eConsent. 💡 https://bit.ly/3rvUFr2

Despite ambitious goals, Pear Therapeutics faced go-to-market challenges and revenue difficulties. Now, nearly one year following Pear’s bankruptcy, the company’s assets have been acquired by four prominent players in the industry. What does this mean for DTx? Let's discuss! Join the waitlist for an insightful discussion on: 🔍 Broader implications for the digital health industry. 🚀 Confidence in digital therapeutics technology and future market shaping. 💡 Revenue generation strategies with innovative product lines. Meeting Full. JOIN THE WAITLIST NOW ➡️ https://lnkd.in/g-ujacYw #digitalhealth #digitaltherapeutics #healthtech

At Insilico Medicine, patients are the ultimate shareholders. "Our primary responsibility is to the shareholders, but patients are ultimate shareholders, those are the people who are suffering today, and if we can cut one year of drug discovery and delivery time for them, we will do that," said Alex Zhavoronkov, founder and CEO of Insilico Medicine on Pharma.ai Day. #PatientFirst #DrugDiscoveryRevolution #FutureOfHealthcare

Breaking News: Merck Healthcare's #Evobrutinib Falls Short in Phase III Trials for #MultipleSclerosis 1️⃣ Merck's Evobrutinib, a #BTK inhibitor, disappoints in Phase III trials for Relapsing Multiple Sclerosis (#RMS). 📉 2️⃣ The EVOLUTION trials (evolutionRMS 1 & 2) show Evobrutinib failing to meet primary endpoints in ARR reduction. 🎯 3️⃣ Evobrutinib's ARR: 0.11 in evolutionRMS 1 and 0.15 in evolutionRMS 2, on par with oral teriflunomide. 🆚 4️⃣ Surprisingly, Teriflunomide's ARR lower than in recent Phase III studies. 🤔 5️⃣ The safety profile of Evobrutinib aligns with Phase II results, indicating consistent tolerability. ✅ 6️⃣ Merck's R&D head expresses disappointment but remains committed to advancing healthcare strategies. 💬 7️⃣ The focus shifts towards enhancing marketed portfolio and internal pipeline, supplemented by external innovation. 🔄 Like / share this post to see more like it! Reach out to #LucidQuest at info@lqventures.com to find out more about what we do and how we can support your brand to thrive! #lucidquest #Merck #MultipleSclerosis #Evobrutinib #HealthcareInnovation #ClinicalTrials #MedicalResearch #PharmaIndustry #BiotechNews #RMS #PatientCare #ScienceAndTechnology #HealthcareStrategy #DrugDevelopment #MedicalBreakthrough

What steps will you take to ensure your new, innovative radiopharmaceutical delivers on its clinical promise and achieves successful commercial adoption? We've got some suggestions. Tune in to Fractals: Life Science Conversations with guest Andrew Beck to unravel the mysteries of the radiopharmaceutical 'unk-unk', understand the significance of patient education in sales, and learn why an integrated approach is pivotal for effective strategy. https://lnkd.in/gspsAYfq #Radiopharmaceuticals #CommercializationStrategy #LifeSci #Bracken

Positive news from Inventiva Pharma about the NATIVE Phase IIb clinical trial data published in Nature Communications. From today's media release: ► Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure. ► Among the patients who had prediabetes at study entry and were treated with lanifibranor, the majority had fasting glucose levels within the normal range at the end of treatment. No patient treated with lanifibranor with normal glucose levels at study entry progressed to prediabetes during treatment, unlike in the placebo arm. ► Adiponectin levels were increased by lanifibranor while they remained low and unchanged under placebo. Adiponectin increase was correlated with improvement of cardiometabolic health. ► A greater proportion of patients with MASH/NASH and high cardiovascular risk treated with either dose of lanifibranor saw their cardiovascular risk improved to intermediate or low risk compared to patients in the placebo arm. ► Improvements in cardiometabolic health markers were similar regardless of the patients’ diabetes and obesity status and regardless of weight change during treatment with lanifibranor. Source: Cooreman, M.P., Butler, J., Giugliano, R.P. et al. The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis. Nat Commun 15, 3962 (2024). https://lnkd.in/gJCDHyTy American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Global NASH Council, Manal Abdelmalek, Sven Francque, Arun Sanyal, Global Liver Institute, Barcelona Institute for Global Health (ISGlobal), Michael C., Jeffrey V. Lazarus

In this K-Cast, Diana Brixner, PhD, FAMCP, explores how the US FDA and industry associations define, identify and evaluate digital therapeutics, including nonprescription digital tools and interventions. Watch the episode here: https://bit.ly/3VyfxKV #ManagedCare #DigitalHealth Diana Brixner

Dermal drug delivery is a popular method for administering therapeutics, and a preferential route because of its ease of use, and potential to enhance user compliance during clinical trials. In issue 39 of The Altascientist, we look at some of the approaches and considerations needed for advancing your dermal studies, from nonclinical to Phase I clinical trials. Learn more: https://lnkd.in/g5PiNsaV #ClinicalTrials #DrugDevelopment #DermalStudies

Check out BioPharma's latest article highlighting the top 10 clinical trials to watch in the second half of 2024. From groundbreaking therapies to potential game-changers, these trials are paving the way for the future of healthcare. Dive into the details below! . #Biotech #ClinicalTrials #HealthcareInnovation #medicalaffairs